Professor Abhay Pandit is the Established Professor in Biomaterials. He is the Director of a Science Foundation Ireland funded Centre for Research in Medical Devices (CÚRAM) at the the National University of Ireland, Galway. He obtained a PhD from the University of Alabama at Birmingham, where his postgraduate work focussed on the modification of a fibrin scaffold to deliver a therapeutic biomolecule and resulted in a clinical trial at the Burn Centre. Prof Pandit has over twenty-five years of experience in the field of biomaterials. After a seven-year stint in industry he has worked in academia for the last twelve years. His research is funded by Science Foundation Ireland, the 7th EU Framework programme, Enterprise Ireland, Health Research Board, the AO Foundation and industry sources, and in excess of €78 million. He is the author of 4 patents and has licensed three technologies to medical device companies. He has published more than 180 manuscripts in high-impact factor publications. He was inducted as an International Fellow in Biomaterials Science and Engineering by the International Union of Societies for Biomaterials Science and Engineering (IUSBSE). He has been elected as a Council Member of the Tissue Engineering and Regenerative Medicine and the International Society and European Society for Biomaterials.

Biomaterial Functionalisation

Prof Pandit's research program utilises foundation platform technologies to drive disruptive change through a synergistic network of national and international academic, clinical and industrial collaborations. They develop hierarchical biomaterial constructs coupled with tailored functionalisation strategies. Biochemical functionalisation with carbohydrates, nucleic acids, antibodies and peptides are designed to influence fundamental physiological processes with high potency and selectivity. Prof Pandit develops functional, biocompatible building blocks encompassing synthetic and natural polymers, tailored glycomolecules, small molecules nucleic acids targeting systems and cellular elements. These platforms include targeted controlled-drug-release systems and multi-component biomaterial-based selective delivery systems and the synthesis of electrically responsive materials, cyclic polymers and functional branched poly(amino acid) as well as peptidomimetics and glycan conjugates. These macromolecular complexes form functional interfaces between implanted devices and biological systems to endow the former with bio-responsiveness and/or biological function. In addition, hierarchically assembled micro- and nano-structured implants and devices are designed to emulate fundamental cellular architecture and offer control over cellular function, enable cell phenotype maintenance, enhance matrix deposition and facilitate acceptance and clinical translation of cell-based devices. These platforms have been developed for musculoskeletal, cardiovascular, soft tissue repair and neural targets with a number of others targets currently under investigation.